CA3253043A1 - GLP-1-BASED PHARMACEUTICAL COMPOSITIONS - Google Patents
GLP-1-BASED PHARMACEUTICAL COMPOSITIONSInfo
- Publication number
- CA3253043A1 CA3253043A1 CA3253043A CA3253043A CA3253043A1 CA 3253043 A1 CA3253043 A1 CA 3253043A1 CA 3253043 A CA3253043 A CA 3253043A CA 3253043 A CA3253043 A CA 3253043A CA 3253043 A1 CA3253043 A1 CA 3253043A1
- Authority
- CA
- Canada
- Prior art keywords
- glp1
- pharmaceutical compositions
- pharmaceutical
- compositions
- glp1 pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263340591P | 2022-05-11 | 2022-05-11 | |
| US63/340,591 | 2022-05-11 | ||
| PCT/US2023/021637 WO2023220109A1 (en) | 2022-05-11 | 2023-05-10 | Glp1 pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3253043A1 true CA3253043A1 (en) | 2023-11-16 |
Family
ID=86732348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3253043A Pending CA3253043A1 (en) | 2022-05-11 | 2023-05-10 | GLP-1-BASED PHARMACEUTICAL COMPOSITIONS |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20250302809A1 (enExample) |
| EP (1) | EP4522129A1 (enExample) |
| JP (1) | JP7767651B2 (enExample) |
| KR (1) | KR20250002778A (enExample) |
| CN (1) | CN119173255A (enExample) |
| AR (1) | AR129296A1 (enExample) |
| AU (1) | AU2023269995A1 (enExample) |
| CA (1) | CA3253043A1 (enExample) |
| CL (1) | CL2024003392A1 (enExample) |
| CO (1) | CO2024015285A2 (enExample) |
| DO (1) | DOP2024000232A (enExample) |
| IL (1) | IL316629A (enExample) |
| MX (1) | MX2024013839A (enExample) |
| PE (1) | PE20251285A1 (enExample) |
| TW (2) | TWI867526B (enExample) |
| WO (1) | WO2023220109A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12234236B1 (en) | 2023-09-14 | 2025-02-25 | Ascletis Pharma (China) Co., Limited | GLP-1R agonist and therapeutic method thereof |
| WO2025108361A1 (zh) * | 2023-11-21 | 2025-05-30 | 江苏恒瑞医药股份有限公司 | 杂环类化合物、其制备方法及其在医药上的应用 |
| TW202521534A (zh) | 2023-11-24 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
| WO2025189141A1 (en) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Methods for treating obesity and increasing weight loss |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004520398A (ja) * | 2001-01-18 | 2004-07-08 | ファルマシア・アンド・アップジョン・カンパニー | 経口生物学的利用能が改善されたパクリタキセルの化学療法マイクロエマルジョン組成物 |
| US7115565B2 (en) * | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| CA2662748A1 (en) * | 2006-09-08 | 2008-03-13 | Merck & Co., Inc. | Liquid pharmaceutical formulations for oral administration of a cgrp antagonist |
| JOP20190060A1 (ar) * | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| JP7461104B2 (ja) * | 2017-11-29 | 2024-04-03 | 中外製薬株式会社 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
| TW202446384A (zh) | 2018-12-07 | 2024-12-01 | 美商紐羅克里生物科學有限公司 | 用於治療先天性腎上腺增生之crf1受體拮抗劑、醫藥配方及其固體形式 |
| US11884672B2 (en) | 2019-05-14 | 2024-01-30 | Vertex Pharmaceuticals Incorporated | Modulators of alpha-1 antitrypsin |
| ES3040117T3 (en) | 2020-09-09 | 2025-10-28 | Crinetics Pharmaceuticals Inc | Formulations of a somatostatin modulator |
| IL316478A (en) | 2022-05-11 | 2024-12-01 | Lilly Co Eli | GLP1 tablet preparations |
-
2023
- 2023-05-10 KR KR1020247040462A patent/KR20250002778A/ko active Pending
- 2023-05-10 WO PCT/US2023/021637 patent/WO2023220109A1/en not_active Ceased
- 2023-05-10 AU AU2023269995A patent/AU2023269995A1/en active Pending
- 2023-05-10 EP EP23729579.5A patent/EP4522129A1/en active Pending
- 2023-05-10 PE PE2024002463A patent/PE20251285A1/es unknown
- 2023-05-10 CA CA3253043A patent/CA3253043A1/en active Pending
- 2023-05-10 CN CN202380039380.7A patent/CN119173255A/zh active Pending
- 2023-05-10 JP JP2024566219A patent/JP7767651B2/ja active Active
- 2023-05-10 US US18/864,210 patent/US20250302809A1/en active Pending
- 2023-05-10 IL IL316629A patent/IL316629A/en unknown
- 2023-05-11 TW TW112117510A patent/TWI867526B/zh active
- 2023-05-11 TW TW113144409A patent/TW202508581A/zh unknown
- 2023-05-11 AR ARP230101165A patent/AR129296A1/es unknown
-
2024
- 2024-11-06 CL CL2024003392A patent/CL2024003392A1/es unknown
- 2024-11-08 CO CONC2024/0015285A patent/CO2024015285A2/es unknown
- 2024-11-08 MX MX2024013839A patent/MX2024013839A/es unknown
- 2024-11-11 DO DO2024000232A patent/DOP2024000232A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2024003392A1 (es) | 2025-03-14 |
| PE20251285A1 (es) | 2025-05-14 |
| AR129296A1 (es) | 2024-08-07 |
| US20250302809A1 (en) | 2025-10-02 |
| KR20250002778A (ko) | 2025-01-07 |
| DOP2024000232A (es) | 2024-12-30 |
| EP4522129A1 (en) | 2025-03-19 |
| JP7767651B2 (ja) | 2025-11-11 |
| CN119173255A (zh) | 2024-12-20 |
| TW202508581A (zh) | 2025-03-01 |
| WO2023220109A1 (en) | 2023-11-16 |
| TW202410894A (zh) | 2024-03-16 |
| CO2024015285A2 (es) | 2024-11-28 |
| TWI867526B (zh) | 2024-12-21 |
| IL316629A (en) | 2024-12-01 |
| JP2025515706A (ja) | 2025-05-20 |
| MX2024013839A (es) | 2024-12-06 |
| AU2023269995A1 (en) | 2024-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3253043A1 (en) | GLP-1-BASED PHARMACEUTICAL COMPOSITIONS | |
| CA3252057A1 (en) | GLP-1 TABLET COMPOSITION | |
| CA3263545A1 (en) | LIQUID PHARMACEUTICAL COMPOSITION | |
| EP4175626A4 (en) | NEW PHARMACEUTICAL COMPOSITIONS | |
| EP4230210A4 (en) | STABLE PHARMACEUTICAL COMPOSITION | |
| EP3914234A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| HK40117304A (en) | Glp1 pharmaceutical compositions | |
| IL314046A (en) | RIBOCICLIB medicinal preparations | |
| HK40117302A (en) | Glp1 tablet compositions | |
| HK40117282A (zh) | 氯苯唑酸药物组合物 | |
| AU2024279893A1 (en) | Pharmaceutical compositions | |
| CA3274331A1 (en) | Milvexian pharmaceutical compositions | |
| AU2024217663A1 (en) | Milvexian pharmaceutical compositions | |
| HK40112458A (en) | Ribociclib pharmaceutical compositions | |
| HK40121850A (zh) | 医药组合物 | |
| AU2023901609A0 (en) | Pharmaceutical composition | |
| HK40122488A (zh) | 包含森塔纳法啶的药物组合物 | |
| CA3264627A1 (en) | SOLID PHARMACEUTICAL COMPOSITIONS OF ADAGRASIB | |
| CA3261419A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING CENTANAFADINE | |
| HK40116526A (zh) | 包含美洛昔康的药物组合物 | |
| HK40107805A (zh) | 药物组合物 | |
| HK40096042A (en) | Pharmaceutical compositions | |
| HK40088134A (zh) | 药物组合物 | |
| HK40118932A (en) | Pharmaceutical composition | |
| HK40106463A (zh) | 包含对硼苯丙氨酸的药物组合物 |